AstraZeneca signed a deal with Alteogen worth up to $1.35 billion for subcutaneous cancer drugs. Taiho Pharmacetical bought ...
Zacks Investment Research on MSN3h
J&J's Tremfya Gets FDA Nod for 2nd IBD Condition Crohn's DiseaseJohnson & Johnson JNJ announced that the FDA has granted approval to its key drug, Tremfya, for its second inflammatory bowel ...
Gene therapy pioneer Jim Wilson and researcher Kiran Musunuru are using contrasting approaches to overcome “irrational ...
Immunovant (NASDAQ:IMVT – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in ...
Immunovant (IMVT) reported best absolute improvements with IMVT-1402 in myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, and while H.C. Wainwright analyst Douglas Tsao was ...
Investor's Business Daily on MSN19h
ARS Pharma Retakes Its 50-Day Line In Bullish Post-Earnings Move. Here's Why.Shares of ARS Pharmaceuticals bounded off their 50-day line Thursday after the biotech company reported an unexpected ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback